Brief: Biofrontera Inc. Announces Filing Of Supplemental New Drug Application
02/12/2025 13:49
Dec 2 (Reuters) - Biofrontera Inc BFRI.O: BIOFRONTERA INC. ANNOUNCES FILING OF SUPPLEMENTAL NEW DRUG APPLICATION (SNDA) FOR THE TREATMENT OF SUPERFICIAL BASAL CELL CARCINOMA (SBCC) WITH AMELUZ®-PDT BIOFRONTERA: FILING SEEKS TO EXPAND AMELUZ LABEL TO INCLUDE TREATMENT OF SBCC TREATMENT WITH PDT USING ITS BF-RHODOLED OR RHODOLED XL RED LIGHT LAMPS Source text: ID:nGNX28MGMl Further company coverage: BFRI.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biofrontera
See all newsBrief: Biofrontera Submits Supplemental New Drug Application To FDA To Expand Ameluz® Red Light Pdt To Actinic Keratoses On The Full Body
Biofrontera Inc reports results for the quarter ended June 30 - Earnings Summary
Biofrontera Q2 revenue rises on higher volume, pricing
Biofrontera Inc expected to post a loss of 10 cents a share - Earnings Preview
Biofrontera Q1 revenue rises on higher Ameluz sales